|

Gemcitabin Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University1
  • Blokhin's Russian Cancer Research Center1

Indications

  • Cancer2
  • BCG-Unresponsive Bladder Cancer1
  • Biliary Tract Cancer (BTC)1
  • Non-Muscle Invasive Bladder Cancer1

Other2 trials

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
N/A
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.